146P Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer

Abstract

Moreover, only 1/4 RAD51-low/TIL-high tumors achieved pCR but none of them relapsed. Conclusions:The RAD51 test is able to identify HRR-altered tumors, beyond gBRCA1/ 2 mutations, and to select a cohort of RAD51-low pts with better prognosis in a platinum-free neoCT setting. Biomarker analyses on treated paired tumors and on a larger cohort of pts are ongoing. Results will be available for the congress.Legal entity responsible for the study: The authors.